Methods for inhibiting HIV-1 infection
View Patent ↗This invention provides a method of reducing an HIV infected subject's HIV-1 viral load which comprises administering to the subject an effective viral load reducing amount of an antibody which (a) binds to a CCR5 chemokine receptor and (b) inhibits fusion of HIV-1 to a CD4+CCR5+cell, so as to thereby reduce the subject's HIV-1 viral load to 50% or less of the subject's HIV-1 viral load prior to administering the antibody to the subject.
1. A method of reducing HIV-1 viral load in an HIV-1 infected subject which comprises administering to the subject solely post-infection an effective viral load-reducing amount of an agent which comprises a CDR domain of an anit-CCR5 antibody, which agent is monoclonal antibody PA14 (ATCC Accession No. HB-12610) or competes with PA14 for binding to an epitope on a human CCR5 chemokine receptor, so as to thereby reduce the subject's HIV-1 viral load to 50% or less of the subject's HIV-1 viral load prior to administration of any of the antibody to the subject.
2. The method of claim 1 , wherein the subject's HIB-1 viral load is reduced to 33% or less of the subject's HIV-1 viral load prior to administration of any of the antibody to the subject.
3. The method of claim 1 , wherein the subject's HIV-1 viral load is reduced to 10% or less of the subject's HIV-1 viral load prior to administration of any of the antibody to the subject.
4. The method of claim 1 , wherein the reduction of the subject's HIV-1 viral load is sustained for at least one day.
5. The method of claim 4 , wherein the reduction is sustained for at least three days.
6. The method of claim 5 , wherein the reduction is sustained for at least seven days.
7. The method of claim 6 , wherein the antibody is PA14 (ATCC Acession No. HB-12610).
8. The method of claim 6 or 7 , wherein the effective amount of the antibody is between 0.1 mg and 100 mg per kg body weight of the subject.
9. The method of claim 8 , wherein the effective amount of the antibody is between 1 and 50 mg per kg body weight of the subject.
10. The method of claim 9 , wherein the effective amount of the antibody is between 2 mg and 40 mg per kg body weight of the subject.
11. The method of claim 10 , wherein the effective amount of the antibody is between 3 and 30 mg per kg body weight of the subject.
12. The method of claim 11 , wherein the effective amount of the antibody is between 4 and 20 mg per kg body weight of the subject.
13. The method of claim 12 , wherein the effective amount of the antibody is between 5 and 10 mg per kg body weight of the subject.
14. The method of claim 6 or 7 , wherein the antibody is administered at least once per day.
15. The method of claim 14 , wherein the antibody is administered daily.
16. The method of claim 6 or 7 , wherein the antibody is administered every other day.
17. The method of claim 6 or 7 , wherein the antibody is administered every 6 to 8 days.
18. The method of claim 17 , wherein the antibody is administered weekly.
19. The method of claim 6 or 7 , wherein the antibody is administered intravenously, subcutaneously, intramuscularly, intraperitoneally, orally or topically.
20. The method of claim 6 , wherein the subject is a human being and the antibody is a human antibody.
21. The method of claim 6 , wherein the subject is a human being and the antibody is a humanized antibody.
22. The method of claim 6 , wherein the antibody is a chimeric antibody.
23. The method of claim 1 , further comprising administering at least one compound which binds to a gp41 subunit of HIV-1 envelope glycoprotein.
24. The method of claim 23 , wherein the at least one compound is the T-20 inhibitor of HIV-1 entry.